Kymera Therapeutics (NASDAQ:KYMR) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $85.00 target price on the stock. KYMR has been the subject of several other reports. Truist Financial started coverage on Kymera Therapeutics in a […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Raymond James ,Pricet Rowe Associates Inc ,Kymera Therapeutics Inc ,Artal Group ,Wellington Management Group ,Avoro Capital Advisors ,Kymera Therapeutics Company Profile ,Kymera Therapeutics ,Free Report ,Moderate Buy ,Therapeutics Trading Down ,Get Free Report ,Capital Advisors ,Street Corp ,Management Group ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Reiterated Rating ,Hc Wainwright ,